Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 4/F, Professorial Block, 102 Pokfulam Road, Pokfulam, Hong Kong, Special Administrative Region, China.
Respir Res. 2023 Feb 14;24(1):53. doi: 10.1186/s12931-023-02363-z.
While there are postulations that asthma is potentially associated with severe coronavirus disease 2019 (COVID-19), there has been conflicting results from studies on the impact mild-to-moderate COVID-19 on asthma control after recovery.
A case control study on the association between mild-to-moderate COVID-19 and asthma control post infection was conducted. The primary outcome was a reduction in Asthma Control Test (ACT) score by ≥ 3 points post-COVID infection. The secondary outcomes included the change in ACT score, the proportion of patient with ACT score who dropped to ≤ 15 on enrolment visit and the need for escalation of asthma maintenance therapy.
Out of the total of 221 adult patients with asthma recruited, 111 had mild-to-moderate COVID-19 within 30 to 270 days prior to study enrolment. The adjusted odds ratio (aOR) for a reduction in ACT score by ≥ 3 points after COVID-19 was 3.105 (95% CI = 1.385-6.959, p = 0.006). The odds of escalation of asthma maintenance therapy by at least 1 Global Initiative for Asthma (GINA) step was 4.733 (95% CI = 1.151-19.467, p = 0.031) and asthma patient are more likely to become uncontrolled after COVID-19 [aOR = 5.509 (95% CI = 1.061-28.600, p = 0.042)].
Mild-to-moderate COVID-19 among asthma patients, upon recovery, was associated with worsening of asthma symptom, lower ACT score, a higher need for escalation of asthma maintenance therapy and more uncontrolled asthma.
虽然有推测认为哮喘可能与严重的 2019 年冠状病毒病(COVID-19)有关,但关于轻度至中度 COVID-19 对康复后哮喘控制的影响,研究结果却存在矛盾。
进行了一项关于轻度至中度 COVID-19 与感染后哮喘控制之间关联的病例对照研究。主要结局是 COVID 感染后哮喘控制测试(ACT)评分降低≥3 分。次要结局包括 ACT 评分的变化、入组时 ACT 评分降至≤15 的患者比例以及哮喘维持治疗升级的需要。
在总共招募的 221 名成年哮喘患者中,有 111 名在研究入组前 30 至 270 天内患有轻度至中度 COVID-19。COVID-19 后 ACT 评分降低≥3 分的调整优势比(aOR)为 3.105(95%CI=1.385-6.959,p=0.006)。至少升级 1 个全球哮喘倡议(GINA)步骤的哮喘维持治疗升级的几率为 4.733(95%CI=1.151-19.467,p=0.031),并且 COVID-19 后哮喘患者更有可能变得无法控制[aOR=5.509(95%CI=1.061-28.600,p=0.042)]。
哮喘患者在康复后患有轻度至中度 COVID-19 与哮喘症状恶化、ACT 评分降低、需要升级哮喘维持治疗以及更多无法控制的哮喘有关。